TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34067524
Drug: Magnesium supplement
Normalized name: Magnesium supplement
DrugBank: Magnesium chloride (DB09407)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnesium supplement (450 mg for men, 300 mg for women)
Study: 34067524
Drug: Control (water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (water without magnesium supplement)
Study: 33306418
Drug: Denosumab biosimilar
Normalized name: Denosumab
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Denosumab biosimilar (60 mg)
Study: 35338860
Drug: Probiotic peanut
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic peanut oral immunotherapy
Study: 33798499
Drug: ChAdOx1 nCoV-19
Normalized name: ChAdOx1 nCoV-19
DrugBank: AstraZeneca COVID-19 Vaccine (DB15656)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChAdOx1 nCoV-19 (AZD1222) vaccine
Study: 36342343
Drug: Ketanserin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (40 mg p.o.)
Study: 32410715
Drug: Video games
Normalized name: Encora AM Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Video games not specifically designed to train cognition (CC) + endurance, strength, and music-movement coordination (EI)
Study: 32410715
Drug: Video games
Normalized name: Encora AM Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Video games not specifically designed to train cognition (CC) + stretching, toning, and relaxation (EC)
Study: 32410715
Drug: Cognitive training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive training (CI or CC) + physical control activity (EC)
Study: 32410715
Drug: Physical training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical training (EI or EC) + cognitive control activity (CC)
Study: 32410715
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of both control activities (CC + EC)
Study: 33308122
Drug: Qingpeng ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qingpeng ointment with routine medical treatment and rehabilitative care
Study: 33308122
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment without Qingpeng ointment
Study: 34407826
Drug: Talking therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talking therapy for depression
Study: 32041669
Drug: Intravitreal dexamethasone
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal dexamethasone implant (700 μg)
Study: 36225132
Drug: Edaravone oral
Normalized name: edaravone Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edaravone oral suspension administered orally
Study: 33487257
Drug: Probiotic yogurt
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic yogurt (300 g/d)
Study: 33861440
Drug: Metformin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (500 mg three times daily)
Study: 32048274
Drug: Two consecutive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two consecutive doses of iv dexamethasone 24 mg
Study: 36782325
Drug: Oral azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral azithromycin
Study: 35506388
Drug: Dihydropyridine calcium
Normalized name: 4-(2'-Nitrophenyl)-2,6-dimethyl-1,4-dihydropyridin-3,5-dicarbonsäuredimethylester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydropyridine calcium channel blockers
Study: 35665728
Drug: Nintedanib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nintedanib plus pirfenidone (combination group)
Study: 33177138
Drug: No discontinuation
Approvals — FDA: no, EMA: no, PMDA: no
Description: No discontinuation
Study: 33248570
Drug: 30 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/kg virginiamycin (antibiotic)
Study: 35088616
Drug: Questionnaires administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Questionnaires administered via paper booklets, interactive voice response system, or tablet web survey
Study: 32896653
Drug: Viaskin-PT 25
Normalized name: PT-2385
DrugBank: PT-2385 (DB16055)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viaskin-PT 25 μg
Study: 32896653
Drug: Viaskin-PT 50
Normalized name: PT-2385
DrugBank: PT-2385 (DB16055)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viaskin-PT 50 μg
Study: 37330602
Drug: mRNA-1273 vaccine
Normalized name: SARS-CoV-2 mRNA-1273 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA-1273 vaccine
Study: 34269848
Drug: MB02 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: MB02 (3 mg/kg IV dose)
Study: 34269848
Drug: Reference bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Reference bevacizumab (3 mg/kg IV dose)
Study: 32771276
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg IV every 3 weeks and PLD 40 mg/m2 IV every 4 weeks
Study: 32771276
Drug: Pembrolizumab and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab and PLD combination therapy
Study: 33729323
Drug: Chahuang ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chahuang ointment
Study: 33729323
Drug: Mucopolysaccharide Polysulfate
Normalized name: Mucopolysaccharide polysulfate
DrugBank: Mucopolysaccharide polysulphate (DB16564)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mucopolysaccharide Polysulfate cream
Study: 33161472
Drug: Sunscreen formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunscreen formulations with nanostructured lipid carriers (NLCs) containing quercetin
Study: 33161472
Drug: Sunscreen formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunscreen formulations without antioxidants
Study: 32452208
Drug: HGH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: HGH treatment
Study: 33000891
Drug: Long-term injectable
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term injectable opioid agonist treatment with diacetylmorphine (DAM)
Study: 36526521
Drug: Everolimus (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus (10 mg daily)
Study: 33764619
Drug: CX-8998 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: CX-8998 (10 mg twice daily)
Study: 35365958
Drug: Weekly administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly administration of low-dose methotrexate (12.5 mg once per week)
Study: 35365958
Drug: Both daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both daily and weekly administration of low-dose methotrexate
Study: 35365958
Drug: Daily and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily and weekly administration of low-dose methotrexate
Study: 616038469
Drug: Topical brinzolamide
Normalized name: Brinzolamide
DrugBank: Brinzolamide (DB01194)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical brinzolamide bid for 2 weeks followed by intravitreal bevacizumab
Study: 36164983
Drug: Cocoa flavanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocoa flavanol (CF) 1350 mg
Study: 34520130
Drug: Inhaled bronchodilators
Normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled bronchodilators (6 weeks)
Study: 34520130
Drug: Inhaled bronchodilators
Normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled bronchodilators + inhaled corticosteroids (ICS) (12 weeks)
Study: 34520130
Drug: Inhaled bronchodilators
Normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled bronchodilators + ICS
Study: 34570004
Drug: Web-based training,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based training, four-session telephone follow-up, and one text message weekly
Study: 32109257
Drug: Adaptable implementation
Normalized name: ADAPT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adaptable implementation package targeting co-prescription of aspirin and clopidogrel without gastro-protection
Study: 33177324
Drug: Hydrocodone administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocodone administration by parents with high anxiety
Study: 33177324
Drug: Hydrocodone administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocodone administration by parents with high stress
Study: 33177324
Drug: Acetaminophen administration
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen administration influenced by parental coping styles
Study: 39311597
Drug: Placebo injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injections
Study: 32505171
Drug: No glucose
Normalized name: No glucose hemofiltration solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: No glucose infusion (0G group)
Study: 32067100
Drug: Less invasive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Less invasive surfactant administration (LISA)
Study: 32115970
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard treatment of sepsis)
Study: 35079895
Drug: IMO/sucromalt combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMO/sucromalt combination
Study: 34072630
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg of elemental iron as ferrous sulfate
Study: 39709368
Drug: Acceptance and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance and commitment therapy (ACT)
Study: 35929569
Drug: Diaphragm pacemaker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diaphragm pacemaker and pulmonary rehabilitation therapies along with basic ICU nursing and conventional rehabilitation treatment
Study: 35929569
Drug: Basic ICU
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic ICU nursing and conventional rehabilitation treatment
Study: 35929569
Drug: Diaphragm pacemaker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diaphragm pacemaker and pulmonary rehabilitation therapies
Study: 33527332
Drug: Replacement with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Replacement with H2 blockers (Group B)
Study: 33527332
Drug: H2 blockers
Normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: H2 blockers (Group D)
Study: 34511458
Drug: Integrated use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated use of climatic‐, balneo‐ and focused magnetic therapy with anti‐tuberculosis chemotherapy
Study: 34511458
Drug: Drinking mineral
Normalized name: Mineral Oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drinking mineral water 'Teberda' in addition to anti‐tuberculosis chemotherapy
Study: 34511458
Drug: Focused magnetic
Normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Focused magnetic therapy in addition to drinking mineral water 'Teberda' and anti‐tuberculosis chemotherapy
Study: 34511458
Drug: Climatic‐ and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Climatic‐ and anti‐tuberculosis chemotherapy (comparison group)
Study: 33737410
Drug: Co-amoxiclav 400/57
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-amoxiclav 400/57 twice daily for 5 days
Study: 33326711
Drug: HP-3070 7.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: HP-3070 7.6 mg/24 h
Study: 33326711
Drug: HP-3070 3.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: HP-3070 3.8 mg/24 h
Study: 39290680
Drug: Guideline-directed medical
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-directed medical therapy (GDMT) alone
Study: 32562206
Drug: Dabigatran dual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran dual therapy (110 or 150 mg twice daily, with clopidogrel or ticagrelor)
Study: 32562206
Drug: Warfarin triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin triple therapy (with clopidogrel or ticagrelor, and aspirin for 1-3 months)
Study: 35901367
Drug: Engagement-focused parent-teen
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Engagement-focused parent-teen treatment (STAND)
Study: 32864754
Drug: Tetramethylpyrazine nitrone
Normalized name: Tetramethylpyrazine
DrugBank: Ligustrazine (DB19074)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetramethylpyrazine nitrone (TBN) 50-1800 mg IV infusion over 30 min (SAD study)
Study: 32864754
Drug: Tetramethylpyrazine nitrone
Normalized name: Tetramethylpyrazine
DrugBank: Ligustrazine (DB19074)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetramethylpyrazine nitrone (TBN) 700 or 1400 mg twice daily for 6.5 days (MAD study)
Study: 33380585
Drug: Pectoral nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pectoral nerve block with 10 mL of 2% lignocaine as an initial bolus followed by 10 mL every 8 hours up to 24 hours (Group I)
Study: 34059372
Drug: Vaccines For
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccines For Babies (VFB) intervention
Study: 33323886
Drug: Psychological intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Psychological intervention administered by a psychiatrist before surgery and ongoing thereafter
Study: 33302648
Drug: Polyethylene glycol
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyethylene glycol 4000, 10 g, twice daily
Study: 34986170
Drug: Zvandiri peer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zvandiri peer counselling with problem-solving therapy (PST)
Study: 37584344
Drug: MF59-adjuvanted vaccine
Normalized name: respiratory syncytial virus pre-fusion F protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF59-adjuvanted vaccine
Study: 35121700
Drug: Oxcarbazepine (900-2400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxcarbazepine (900-2400 mg/day)
Study: 35121700
Drug: Sodium valproate
Normalized name: sodium valproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium valproate (about 20 mg/kg/day)
Study: 32130025
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II infusion for 7 hours at night
Study: 32130025
Drug: Placebo (saline)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline) infusion for 7 hours at night
Study: 38045523
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II infusion
Study: 36282078
Drug: L-arginine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (0.1 mg.kg‐1 daily)
Study: 32335343
Drug: Memantine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine (20 mg/day)
Study: 35300246
Drug: Trimodal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimodal therapy followed by gemcitabine maintenance (Arm A)
Study: 35776901
Drug: Conventional schedule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional schedule radiation therapy
Study: 34217550
Drug: HBM-based rational
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBM-based rational use of drugs training
Study: 39108325
Drug: Placebo twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice daily
Study: 36153030
Drug: Pulmonary rehabilitation
Normalized name: Lobaria pulmonaria extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulmonary rehabilitation (PR) programme comprising 16 twice‐weekly group sessions tailored to the Georgian setting.
Study: 34028828
Drug: Atraumatic restorative
Normalized name: DRESSING,RESTORE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atraumatic restorative treatment and Hall Technique (ART/HT)
Study: 33278014
Drug: Daily Report
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily Report
Study: 36173064
Drug: Repeated-dose intravenous
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated-dose intravenous ketamine
Study: 33004704
Drug: Dexmedetomidine-ketamine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine-ketamine (1 μg/kg dexmedetomidine and 0.5 mg/kg ketamine)
Study: 33004704
Drug: Fentanyl-ketamine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl-ketamine (2 μg/kg fentanyl and 0.5 mg/kg ketamine)
Study: 34233722
Drug: Cybernic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cybernic treatment with HAL (40-min walking program performed nine times)
Study: 34233722
Drug: Hoist only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hoist only treatment
Study: 34233722
Drug: Cybernic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cybernic treatment with HAL
Study: 36332179
Drug: Margetuximab (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Margetuximab (15 mg/kg intravenously once every 3 weeks)
Study: 36332179
Drug: Trastuzumab (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab (6 mg/kg intravenously once every 3 weeks after a loading dose of 8 mg/kg)
Study: 36749915
Drug: Ultrasound treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound treatment
Study: 32227309
Drug: S. salivarius
Approvals — FDA: no, EMA: no, PMDA: no
Description: S. salivarius K12 tablet
Study: 36428171
Drug: Neoadjuvant androgen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant androgen deprivation therapy plus abiraterone with or without apalutamide
Study: 36428171
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (RP without neoadjuvant therapy)
Study: 36087863
Drug: Low-dose IL-2
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose IL-2
Study: 36214032
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (100 kVp, 350 mgI/ml CM)
Study: 36214032
Drug: Group C
Normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C (80 kVp, 320 mgI/ml CM)
Study: 32725293
Drug: 2 portions
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 portions of fish per week (140 g per portion)
Study: 32725293
Drug: 1 portion
Normalized name: XMAB5871 (HUMANIZED ANTI-CD19 ANTIBODY WITH AN FC PORTION ENGINEERED FOR INCREASED AFFINITY (200- TO 400-FOLD OVER NATIVE IGG) TO FCGRIIB)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 portion of fish per week (140 g per portion)
Study: 34110395
Drug: General oncologist
Approvals — FDA: no, EMA: no, PMDA: no
Description: General oncologist treatment style
Study: 33040720
Drug: Trastuzumab treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab treatment
Study: 32966144
Drug: Pneumococcal conjugate
Normalized name: pneumococcal conjugate PCV 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pneumococcal conjugate vaccine (PCV)
Study: 36445398
Drug: Pregnenolone 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregnenolone 300 mg
Study: 36445398
Drug: Pregnenolone 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregnenolone 500 mg
Study: 36445398
Drug: Pregnenolone (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregnenolone (both doses)
Study: 33296549
Drug: Cyclosporine (CSA)
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (CSA) (2.5‐5 mg/kg/d)
Study: 33296549
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) (7.5‐15 mg/week)
Study: 33296549
Drug: Acitretin (ACT)
Normalized name: Acitretin
DrugBank: Acitretin (DB00459)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acitretin (ACT) (25‐50 mg/d)
Study: 32402684
Drug: Oral ferrous
Normalized name: ferrous fumarate Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ferrous fumarate (FF) 200 mg three times a day (total daily dose: 195 mg elemental iron)
Study: 32402684
Drug: Oral ferrous
Normalized name: ferrous fumarate Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ferrous gluconate (FG) 695 mg twice a day (total daily dose: 160 mg elemental iron)
Study: 32402684
Drug: Intravenous ferric
Normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ferric carboxymaltose (FCM) 1000 mg elemental iron (single dose)
Study: 33789963
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment during the third trimester)
Study: 33789963
Drug: TDF therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDF therapy during the third trimester of pregnancy
Study: 35247098
Drug: Wheat aleurone
Normalized name: WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat aleurone (27 g/day)
Study: 35247098
Drug: Cellulose (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cellulose (placebo treatment)
Study: 37610332
Drug: Pharmacological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological treatment
Study: 32275670
Drug: Unilateral radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unilateral radiation therapy
Study: 32275670
Drug: Bilateral radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral radiation therapy
Study: 34308517
Drug: Dabigatran 110
Normalized name: dabigatran 110 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran 110 mg twice daily
Study: 32840598
Drug: Genotype-guided therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genotype-guided therapy (ticagrelor for LOF carriers)
Study: 32840598
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (clopidogrel)
Study: 32840598
Drug: Genotype-guided therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genotype-guided therapy (all randomized patients)
Study: 32840598
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (all randomized patients)
Study: 32840598
Drug: Genotype-guided therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genotype-guided therapy (major or minor bleeding)
Study: 32840598
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (major or minor bleeding)
Study: 34192907
Drug: Smartphone-based care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smartphone-based care platform (treatment group)